Agenus (NASDAQ:AGEN - Get Free Report) is set to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($2.30) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.33) by ($1.19). The company had revenue of $23.51 million during the quarter, compared to analysts' expectations of $64.73 million. During the same quarter in the prior year, the firm posted ($4.00) earnings per share. On average, analysts expect Agenus to post $-11 EPS for the current fiscal year and $-11 EPS for the next fiscal year.
Agenus Price Performance
Shares of AGEN traded up $0.07 during mid-day trading on Wednesday, hitting $4.22. The company's stock had a trading volume of 413,848 shares, compared to its average volume of 640,289. Agenus has a fifty-two week low of $3.96 and a fifty-two week high of $19.69. The stock has a market capitalization of $91.03 million, a price-to-earnings ratio of -0.37 and a beta of 1.39. The firm has a 50-day moving average price of $4.95 and a 200 day moving average price of $9.00.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on AGEN. StockNews.com cut Agenus from a "hold" rating to a "sell" rating in a report on Monday, August 12th. B. Riley reduced their target price on Agenus from $42.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, August 14th. HC Wainwright cut Agenus from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $40.00 to $9.00 in a research note on Thursday, July 18th. Robert W. Baird lowered shares of Agenus from an "outperform" rating to a "neutral" rating and reduced their price objective for the company from $35.00 to $8.00 in a research note on Friday, July 19th. Finally, Baird R W cut shares of Agenus from a "strong-buy" rating to a "hold" rating in a report on Friday, July 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $10.50.
View Our Latest Stock Analysis on Agenus
Agenus Company Profile
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
